Search: onr:"swepub:oai:DiVA.org:uu-430340" >
Dual antithrombotic...
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST elevation myocardial infarction : results from the randomised RE-DUAL PCI trial.
-
Zeymer, Uwe (author)
-
Leiva, Orly (author)
-
Hohnloser, Stefan H (author)
-
show more...
-
Steg, Philippe Gabriel (author)
-
- Oldgren, Jonas, 1964- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
Nickenig, Georg (author)
-
Gabor Kiss, Robert (author)
-
Ongen, Zeki (author)
-
Navarro Estrada, Jose (author)
-
Oude Ophuis, Ton (author)
-
Lip, Gregory Y H (author)
-
Nordaby, Matias (author)
-
Miede, Corinna (author)
-
Ten Berg, Jurrien M (author)
-
Bhatt, Deepak L (author)
-
Cannon, Christopher P (author)
-
show less...
-
(creator_code:org_t)
- Europa Digital & Publishing, 2021
- 2021
- English.
-
In: EuroIntervention. - : Europa Digital & Publishing. - 1774-024X .- 1969-6213. ; 17:6, s. 474-480
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.4...
-
show less...
Abstract
Subject headings
Close
- AIMS: To investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) vs warfarin triple therapy in patients with atrial fibrillation undergoing PCI for ST elevation myocardial infarction (STEMI).METHODS AND RESULTS: In RE-DUAL PCI, 305 patients with STEMI were randomised to dabigatran 110 mg (n=113 versus 106 warfarin) or 150 mg (n=86 versus 84 warfarin). Primary endpoint was time to first major or clinically relevant non-major bleeding event (MBE/CRNMBE). The thrombotic endpoint was a composite of death, thromboembolic events, or unplanned revascularisation. In STEMI patients, dabigatran 110 mg (HR 0.39, 95% CI 0.20-0.74) and 150 mg (0.43, 0.21-0.89) dual therapy reduced the risk of MBE/CRNMBE versus warfarin triple therapy (p interaction vs all other patients = 0.31 and 0.16). Risk of thrombotic events, for dabigatran 110 mg (HR 1.61, 95% CI: 0.85-3.08) and 150 mg (0.56, 0.20-1.51) had p interactions of 0.20 and 0.33, respectively. For net clinical benefit, HRs were 0.74 (95% CI 0.46-1.17) and 0.49 (0.27-0.91) for dabigatran 110 and 150 mg (p interaction = 0.80 and 0.12).CONCLUSIONS: In patients after PCI for STEMI, dabigatran dual therapy had lower risks of bleeding events versus warfarin triple therapy with similar risks of thromboembolic events, supporting the use of dabigatran dual therapy even in patients with high thrombotic risk.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Zeymer, Uwe
-
Leiva, Orly
-
Hohnloser, Stefa ...
-
Steg, Philippe G ...
-
Oldgren, Jonas, ...
-
Nickenig, Georg
-
show more...
-
Gabor Kiss, Robe ...
-
Ongen, Zeki
-
Navarro Estrada, ...
-
Oude Ophuis, Ton
-
Lip, Gregory Y H
-
Nordaby, Matias
-
Miede, Corinna
-
Ten Berg, Jurrie ...
-
Bhatt, Deepak L
-
Cannon, Christop ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
EuroIntervention
- By the university
-
Uppsala University